Hi,<div><br></div><div>I know that some of you are on Azithromycin.</div><div><br></div><div>There was a recent study on inhaled Azithromycin, which was reported in the 2011 cystic fibrosis conference in Hamburg, germany.</div><div><br></div><div>I wonder if anyone out there has tried that or talked to the doctor about it.</div><div><br></div><div>the researched used eFlow and <span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">(100 mg/mL) aqueous azithromycin inhalation solution</div><div><br></div><div>the short version of the study is below:</div><div><br></div><div><span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">Medical rationale for nebulisation of a novel high-concentration<br>(100 mg/mL) aqueous azithromycin inhalation solution<br>M. Keller1, J.M. Schierholz1, U. Schuschnig1, O. Denk1, M. Knoch1. 1PARI<br>Pharma GmbH, Aerosol Research Insitute, Graefelfing, Germany<br>Objective: In addition to its antibiotic activity, Azithromycin (AZM) has antiinflammatory, immunomodulatory and mucus regulating effects. Since oral bioavailability is only about 37%, inhalation can provide high local doses in the airways<br>as the target site to treat CF and bronchiectasis (BE). Topical use of aerosolized<br>azithromycin may increase mucociliary clearance, decrease mucus hypersecretion<br>and reduce IL8, neutrophils, rhinovirus replication, pro-inflammatory proteins, nasal<br>polyps, and protect ciliated epithelium against oxidative damage. Hence, based on<br>such literature data local effects of AZM may improve therapeutic efficacy over oral<br>or i.v. application reducing at the same adverse side effects and resistance formation<br>as known from other inhaled antibiotics.<br>Results: Drug delivery efficiency of a novel taste masked AZM solution<br>(100 mg/mL) utilizing a customised eFlow electronic nebuliser was assessed by<br>breath simulation tests carried out in triplicate, each. In-vitro delivered doses<br>(DDs) of ~75% and respirable dose (RD) of ~50% suggest that a lung deposition<br>of about 40% can be expected. Inhalation tests confirmed good tolerability and<br>acceptable taste.<br>Conclusion: Targeted aerosolized AZM therapy by nebulisation via eFlow technology<br>platform devices may be more advantageous and effective compared to<br>oral application. Hence, the proposed targeted delivery concept of a novel AZM<br>inhalation formulation may open new perspectives for the treatment of CF and BE<br>as well as severe neutrophilic asthma, COPD and mycobacterium avium complex<br>induced infections. Thus, clinical studies are warranted to evaluate the therapeutic<br>value of inhaled Azithromycin.</div>